Last updated: September 23, 2026
Horizon Therapeutics Ireland DAC is no longer an independent public biotechnology company. Amgen completed its acquisition of Horizon Therapeutics plc on October 6, 2023, in a transaction valued at approximately $27.8 billion. Horizon's principal commercial assets are now part of Amgen's rare-disease and inflammation portfolio. The portfolio's value is concentrated in Tepezza, Krystexxa and Uplizna, supported by specialty pharmaceuticals including Ravicti and Procysbi. [1][2]
Horizon’s strongest competitive position is in rare and specialty diseases with limited approved treatment options, high physician concentration and substantial reimbursement barriers. Its main strategic risks are product concentration, biologic competition, manufacturing complexity, payer pressure and the loss of exclusivity for older small-molecule products.
What is Horizon Therapeutics Ireland DAC and who owns it?
Horizon Therapeutics Ireland DAC is an Irish operating entity associated with Horizon Therapeutics plc and its international pharmaceutical activities. Following the Amgen acquisition, the entity operates within Amgen’s corporate structure.
| Item |
Status |
| Legal entity |
Horizon Therapeutics Ireland DAC |
| Former parent |
Horizon Therapeutics plc |
| Current parent |
Amgen Inc. |
| Acquisition closing |
October 6, 2023 |
| Transaction value |
Approximately $27.8 billion |
| Primary business |
Rare disease, rheumatology and specialty medicines |
| Core commercial assets |
Tepezza, Krystexxa, Uplizna, Ravicti and Procysbi |
| Principal geographic markets |
United States, Europe and selected international markets |
The acquisition followed a Federal Trade Commission review. The FTC required Amgen to divest certain rights relating to Tepezza and other medicines to preserve competition in specified markets. [3]
Why does Horizon remain strategically important to Amgen?
Horizon supplied Amgen with commercial products in therapeutic areas where Amgen had less direct exposure, particularly thyroid eye disease, chronic refractory gout and neuromyelitis optica spectrum disorder. The transaction also gave Amgen a specialty commercial infrastructure covering rare-disease diagnosis, reimbursement and patient-support programs.
The portfolio is commercially attractive because several products address diseases with small patient populations but high annual treatment costs. Its economics depend less on broad primary-care prescribing and more on specialist adoption, payer approval and sustained treatment duration.
What products does Horizon Therapeutics sell?
Tepezza
Tepezza, or teprotumumab-trbw, is an intravenous biologic approved by the FDA for thyroid eye disease, also known as thyroid-associated ophthalmopathy. It is the first FDA-approved medicine specifically indicated for thyroid eye disease.
Tepezza has been Horizon’s most visible growth asset. The product benefits from:
- A first-mover position in thyroid eye disease.
- Limited direct therapeutic substitution.
- Treatment through specialist infusion centers.
- High unmet need among patients with active and chronic disease.
- A disease area with concentrated ophthalmology and endocrinology prescribers.
Competitive risk comes from off-label immunosuppressive therapy, surgery, radiotherapy and emerging biologic approaches. Tepezza also faces safety, access and reimbursement scrutiny, including concerns relating to hearing impairment and patient selection.
Tepezza is a biologic and therefore does not receive traditional Orange Book patent listing in the same way as a small-molecule tablet. Its protection depends on biologic exclusivity, patents, regulatory exclusivity and the difficulty of developing a competing product under the biosimilar pathway.
Krystexxa
Krystexxa, or pegloticase, is an intravenous biologic used for chronic gout in adults who have not responded adequately to conventional treatment. Its mechanism differs from standard urate-lowering drugs because it enzymatically metabolizes uric acid.
Krystexxa’s commercial strength increased after the company developed co-therapy approaches intended to reduce anti-drug antibodies and improve treatment persistence. The key competitive issue is the size of the eligible refractory-gout population and the ability of physicians to identify patients who require infusion-based treatment.
Competition includes oral urate-lowering therapies such as allopurinol and febuxostat, as well as lifestyle interventions and other specialty approaches. Krystexxa retains differentiation in severe, refractory disease but has a narrower market than conventional gout treatments.
Uplizna
Uplizna, or inebilizumab-cdon, is an anti-CD19 monoclonal antibody approved for adults with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.
Uplizna competes with:
- Soliris and Ultomiris from Alexion, AstraZeneca.
- Enspryng from Roche.
- Rituximab, used off label in some treatment settings.
- Other B-cell-depleting or immunosuppressive regimens.
Uplizna’s differentiation is based on CD19-directed B-cell depletion, dosing convenience after the initial treatment phase and its positioning in a rare autoimmune disease. Its market remains vulnerable to competing biologics, payer step edits and physician preference regarding infusion frequency, safety monitoring and mechanism of action.
Ravicti
Ravicti, or glycerol phenylbutyrate, is an oral nitrogen-binding agent for chronic management of urea cycle disorders. It competes with older nitrogen-scavenging therapies, including sodium phenylbutyrate.
Ravicti’s advantages include palatability, dosing convenience and use in a highly specialized metabolic-disease population. Its risks are more closely connected to reimbursement, generic or authorized-generic competition and the relatively limited number of diagnosed patients than to direct biologic competition.
Procysbi
Procysbi, or delayed-release cysteamine bitartrate, is used for the management of nephropathic cystinosis. It competes with immediate-release cysteamine products and other supportive treatments.
Its principal commercial differentiation is delayed-release administration, which can reduce dosing frequency and improve treatment burden. The product remains exposed to generic substitution and payer efforts to prefer lower-cost cysteamine alternatives.
How strong is Horizon’s patent and exclusivity position?
Horizon’s patent strength differs materially by product.
| Product |
Modality |
Regulatory protection profile |
Principal risk |
| Tepezza |
Monoclonal antibody |
Biologic exclusivity, formulation and manufacturing patents, potential biosimilar barriers |
Biosimilar development, payer controls and safety scrutiny |
| Krystexxa |
PEGylated enzyme biologic |
Biologic exclusivity and biologic-process protection |
Competing biologics, treatment economics and infusion burden |
| Uplizna |
Monoclonal antibody |
Biologic exclusivity, antibody and manufacturing patents |
Competing autoimmune biologics and biosimilars |
| Ravicti |
Small molecule |
Orange Book patents, pediatric and other regulatory protections |
Generic or authorized-generic entry |
| Procysbi |
Small molecule formulation |
Formulation and delivery patents, Orange Book-related protection |
Formulation patent challenges and generic substitution |
The estate is strongest where product differentiation depends on a complex biologic, specialized manufacturing and a narrow disease population. Biologic protection does not eliminate competition. Biosimilar developers can challenge patent rights, pursue non-infringing products or wait for regulatory exclusivity to expire.
The estate is less durable for oral products because formulation patents can be challenged through Paragraph IV certifications and because physicians and payers can substitute older therapies.
What is the Orange Book status of Horizon products?
Ravicti and Procysbi are small-molecule products for which Orange Book-listed patents and exclusivity are relevant. Tepezza, Krystexxa and Uplizna are biologics regulated through the Public Health Service Act and are not protected through ordinary Orange Book listing as conventional small molecules.
For small-molecule products, a generic applicant may submit an abbreviated new drug application with a Paragraph IV certification asserting that a listed patent is invalid, unenforceable or not infringed. The patent holder can file suit, potentially triggering a 30-month stay under the Hatch-Waxman framework. [4]
For biologics, the relevant framework is the Biologics Price Competition and Innovation Act. The litigation process differs from Hatch-Waxman, and commercial entry depends on biosimilar approval, patent settlements, exclusivity and manufacturing readiness. [5]
When do Horizon products lose exclusivity?
Exact loss-of-exclusivity dates depend on patent scope, patent-term adjustment, pediatric extensions, regulatory exclusivity, settlements and court outcomes. Publicly available product-level dates must be evaluated against current FDA records and patent-office data rather than inferred from launch dates alone.
The commercial timing can be summarized as follows:
| Product |
Near-term exclusivity assessment |
| Tepezza |
Longer-duration biologic and patent protection, but exposed to biosimilar and competing-mechanism development |
| Krystexxa |
Biologic barriers remain material, although competitive biologic development is possible |
| Uplizna |
Rare-disease biologic protection is supported by manufacturing and clinical complexity |
| Ravicti |
More immediate small-molecule patent and generic-entry risk |
| Procysbi |
Formulation and delivery claims are central to durability and litigation risk |
Product revenue is most vulnerable when a competing therapy obtains a preferred formulary position before formal loss of exclusivity. In rare disease, payer management can reduce net sales before generic or biosimilar entry.
Which companies compete with Horizon and Amgen?
The competitive landscape is product-specific rather than company-wide.
| Horizon product |
Main competitors |
Competitive basis |
| Tepezza |
Emerging thyroid eye disease biologics, surgery and immunosuppressive treatment |
Efficacy, safety, disease stage and treatment duration |
| Krystexxa |
Allopurinol, febuxostat and other gout management approaches |
Cost, route of administration and refractory-disease response |
| Uplizna |
Alexion/AstraZeneca, Roche and off-label rituximab |
Mechanism, relapse prevention, dosing and payer access |
| Ravicti |
Sodium phenylbutyrate and generic alternatives |
Palatability, adherence and price |
| Procysbi |
Immediate-release cysteamine and generic alternatives |
Dosing frequency, tolerability and formulation |
Amgen is the current owner and commercial operator, but the original Horizon assets compete against products from AstraZeneca, Roche, Sanofi, specialty generics manufacturers and emerging biotechnology companies.
What patent litigation and Paragraph IV risks affect Horizon?
The highest Paragraph IV exposure applies to Ravicti and Procysbi because they are small-molecule products. A generic applicant can challenge listed patents after filing an abbreviated application. Litigation may delay entry, narrow the enforceable claims or produce a settlement that permits an agreed launch date.
Tepezza, Krystexxa and Uplizna face a different risk profile. Biosimilar developers must demonstrate analytical similarity, manufacturing comparability and, where required, clinical support. Patent disputes can involve composition, formulation, dosing, antibody sequence, cell lines, purification and manufacturing processes.
Public litigation risk should be assessed across four categories:
- Composition and sequence claims.
- Treatment-method and dosing claims.
- Formulation and delivery claims.
- Manufacturing and purification claims.
Manufacturing patents can be commercially important even when composition claims are weak. A biosimilar sponsor may avoid a composition patent but still need to develop a non-infringing production process with comparable quality attributes.
What manufacturing and intellectual-property barriers protect the portfolio?
Horizon’s biologics have meaningful technical barriers because commercial manufacture requires:
- Qualified cell lines and controlled expression systems.
- Consistent glycosylation and product quality.
- Validated purification and viral-clearance processes.
- Stability data for drug substance and finished product.
- Specialized fill-finish and cold-chain capacity.
- Regulatory comparability packages.
These barriers increase the cost and time required for biosimilar entry. They do not create permanent exclusivity. Amgen’s manufacturing network may improve supply reliability, reduce cost per unit and strengthen global regulatory execution.
The small-molecule products have lower manufacturing barriers. Their defensibility rests more heavily on formulation technology, patient adherence, pediatric use, distribution controls and reimbursement relationships.
How does Horizon compare with other specialty pharmaceutical companies?
| Criterion |
Horizon under Amgen |
Standalone specialty biotechnology |
Large diversified pharmaceutical company |
| Disease focus |
Rare disease and specialty inflammation |
Usually narrower |
Broad |
| Commercial scale |
High, due to Amgen infrastructure |
Limited to moderate |
High |
| Manufacturing capacity |
Strong |
Often outsourced |
Strong |
| Portfolio concentration |
High in a few anchor products |
Often very high |
Lower |
| Pricing leverage |
Strong in rare disease, subject to payer review |
Variable |
Mixed |
| Biosimilar defense |
Improved through Amgen resources |
Often limited |
Usually strong |
| Acquisition flexibility |
Lower after integration into Amgen |
Higher |
Variable |
Horizon’s former advantage was focused commercialization. Amgen’s advantage is scale, capital and global infrastructure. The tradeoff is that Horizon products now compete internally for investment against Amgen’s established oncology, inflammation, cardiovascular and rare-disease programs.
What is the revenue exposure and strategic outlook?
Horizon’s commercial value was concentrated in Tepezza, Krystexxa and Uplizna. This concentration created strong growth potential but increased sensitivity to any safety signal, reimbursement restriction, manufacturing interruption or competing product launch.
Amgen’s strategic priorities are likely to include:
- Expanding diagnosis and treatment rates in thyroid eye disease.
- Maintaining Tepezza access as competing therapies emerge.
- Increasing Uplizna penetration in autoimmune disease.
- Preserving Krystexxa treatment persistence through co-therapy and patient support.
- Extending the life cycle of Ravicti and Procysbi through formulation, geographic and service strategies.
- Using Amgen’s international infrastructure to expand rare-disease access.
- Defending patents while preparing for biosimilar and generic competition.
The strongest growth opportunity is the expansion of specialty biologics into additional autoimmune indications. The main downside risk is that product concentration makes even one major commercial setback visible in Amgen’s growth profile.
What generic and biosimilar launch scenarios exist?
Base case
Amgen retains leading positions in Tepezza, Krystexxa and Uplizna while managing payer restrictions. Older oral products experience gradual pricing pressure rather than an abrupt collapse.
Accelerated erosion case
A successful Paragraph IV challenge, authorized generic or settlement-driven early launch reduces Ravicti or Procysbi revenue faster than expected. A competing biologic also limits Uplizna or Tepezza growth.
Defended-portfolio case
Patent litigation, manufacturing complexity and limited patient populations delay meaningful biosimilar entry. Amgen extends revenue through new indications, dosing strategies and international commercialization.
Commercial disruption case
A safety concern, reimbursement restriction or production issue affects a major biologic. Because revenue is concentrated, the impact would exceed the effect of a similar event in a diversified primary-care portfolio.
What is the geographic coverage of Horizon’s business?
The United States remains the economic center of the portfolio because rare-disease pricing, specialist infrastructure and reimbursement are strongest there. Europe and other markets provide geographic diversification but generally impose greater health-technology assessment, price negotiation and budget controls.
International growth depends on:
- Country-specific reimbursement decisions.
- Local diagnostic capacity.
- Hospital and infusion infrastructure.
- Regulatory recognition of clinical endpoints.
- Pricing references across European markets.
- Supply-chain and cold-chain execution.
Amgen’s global organization is a strategic advantage over Horizon’s former standalone structure, particularly for regulatory submissions and market access.
Key Takeaways
- Horizon Therapeutics Ireland DAC is part of Amgen following the October 2023 acquisition of Horizon Therapeutics plc.
- Tepezza, Krystexxa and Uplizna are the portfolio’s principal strategic assets.
- Tepezza has the strongest commercial differentiation because it was the first FDA-approved thyroid eye disease therapy.
- Uplizna competes directly with major autoimmune biologics from AstraZeneca and Roche.
- Ravicti and Procysbi carry greater conventional generic and Paragraph IV risk than the biologic portfolio.
- Tepezza, Krystexxa and Uplizna depend on biologic exclusivity, patent protection and manufacturing complexity rather than ordinary Orange Book listing.
- Amgen improves Horizon’s manufacturing, regulatory and commercial capabilities but increases internal portfolio competition.
- Revenue concentration remains the central strategic risk.
- The most important diligence areas are product-level patent expiry, current Orange Book entries, biologic patent litigation, biosimilar development and payer access.
FAQs
Is Horizon Therapeutics still an independent company?
No. Amgen completed its acquisition of Horizon Therapeutics plc on October 6, 2023.
Is Tepezza a biologic or a small-molecule drug?
Tepezza is a biologic monoclonal antibody, teprotumumab-trbw. Its competition is governed primarily by biologic exclusivity, patents and the biosimilar pathway.
Does Horizon have products listed in the FDA Orange Book?
Ravicti and Procysbi are small-molecule products for which Orange Book patent and generic-entry rules are relevant. Tepezza, Krystexxa and Uplizna are biologics and are not treated as ordinary Orange Book small molecules.
Which Horizon product has the highest biosimilar risk?
All three major biologics face eventual biosimilar risk, but practical timing depends on patent scope, regulatory exclusivity, manufacturing feasibility and the size of the commercial opportunity. Tepezza has the highest current strategic visibility because of its concentration in the thyroid eye disease market.
What is Horizon’s most defensible competitive advantage?
The strongest advantage is the combination of rare-disease commercial infrastructure, specialist physician relationships, reimbursement expertise and complex biologic manufacturing. These advantages support product durability but do not replace patent and regulatory exclusivity.
References
-
Amgen Inc. (2023). Amgen completes acquisition of Horizon Therapeutics plc. Amgen investor relations.
-
Horizon Therapeutics plc. (2022). Annual report for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.
-
Federal Trade Commission. (2023). FTC accepts proposed consent order settling challenge to Amgen’s acquisition of Horizon Therapeutics. Federal Trade Commission.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable products. FDA.
